| Identification | Back Directory | [Name]
SARS-CoV-2-IN-1 | [CAS]
2412965-59-2 | [Synonyms]
MPro 13b
SARS-CoV-2-IN-1
Mpro inhibitor 13b | [Molecular Formula]
C31H39N5O7 | [MDL Number]
MFCD34469979 | [MOL File]
2412965-59-2.mol | [Molecular Weight]
593.67 |
| Hazard Information | Back Directory | [Description]
MPro 13b is a coronavirus Mpro inhibitor. It inhibits SARS-CoV-2 infection of human Calu3 cells. | [Uses]
SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively[1]. | [in vivo]
SARS-CoV-2-IN-1 (3 mg/kg; subcutaneous) shows the Cmax is 126.2 ng/mL. The mean residence time for SARS-CoV-2-IN-1 is extended to 2.7 hours and the plasma half-life in CD-1 mice is 1.8 hour[1]. | [storage]
Store at -20°C | [References]
[1] Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 Mar 20. pii: eabb3405. DOI:10.1126/science.abb3405 |
|
|